{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:37:34Z","timestamp":1791581854311,"version":"4.3.4"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Metastatic disease: the key unmet need in oncology\u2019 No. 21198"],"award-info":[{"award-number":["Metastatic disease: the key unmet need in oncology\u2019 No. 21198"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00726","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T04:30:06Z","timestamp":1565152206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":103,"title":["Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances"],"prefix":"10.3389","volume":"9","author":[{"given":"Irene","family":"Della Starza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Chiaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"De Propris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia A.","family":"De Novi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Soscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2354.2005.00513.x","article-title":"A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL)","volume":"14","author":"Redaelli","year":"2005","journal-title":"Eur J Cancer Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1007\/s00277-004-0850-2","article-title":"Risk\/MRD adapted GMALL trials in adult ALL","volume":"83","author":"G\u00f6kbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":"Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002","volume":"32","author":"Stary","year":"2014","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 From the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in NGS for MRD Assessment in ALL 489 children with relapsed ALL by risk-stratified salvage therapy: Results of trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-M\u00fcnster Group 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Medical research council of the United Kingdom adult ALL working party; eastern cooperative oncology group. outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"German multicenter study group for adult acute lymphoblastic leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig\/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2141.2008.07350.x","article-title":"Status of minimal residual disease testing in childhood haematological malignancies","volume":"143","author":"Campana","year":"2008","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","article-title":"International BFM Study Group (I-BFM-SG). Minimal residual disease directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia","volume":"22","author":"Flohr","year":"2008","journal-title":"Leukemia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cyto.b.20430","article-title":"Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible","author":"Dworzak","year":"2008","journal-title":"Cytometry B Clin Cytom."},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2141.2011.08795.x","article-title":"Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia","volume":"155","author":"Cazzaniga","year":"2011","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/asheducation-2017.1.13","article-title":"Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation","volume":"1","author":"Br\u00fcggemann","year":"2017","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.09.006","article-title":"Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities","volume":"31","author":"Chen","year":"2017","journal-title":"Blood Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0022-1759(00)00229-5","article-title":"A practical approach to multicolor flow cytometry for immunophenotyping","volume":"243","author":"Baumgarth","year":"2000","journal-title":"J Immunol Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nm0103-112","article-title":"Beyond six colors: a new era in flow cytometry","volume":"9","author":"De Rosa","year":"2003","journal-title":"Nature Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.it.2012.02.010","article-title":"A deep profiler's guide to cytometry","volume":"33","author":"Bendall","year":"2012","journal-title":"Trends Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.290.5491.425","article-title":"Getting a charge out of plastics","volume":"290","author":"Service","year":"2000","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/nm1371","article-title":"Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry","volume":"12","author":"Chattopadhyay","year":"2006","journal-title":"Nature Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/cyto.b.20480","article-title":"Advances in complex multiparameter flow cytometry technology: applications in stem cell research","author":"Preffer","year":"2009","journal-title":"Cytometry B Clin Cytom."},{"key":"B30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/leu.2012.231","article-title":"Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"27","author":"Denys","year":"2012","journal-title":"Leukemia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/bmt.2008.122","article-title":"B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL","volume":"42","author":"Fronkova","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2018.09.008","article-title":"Frequent issues and lessons learned from EuroFlow QA","author":"Kalina","year":"2018","journal-title":"J Immunol Methods."},{"key":"B36","first-page":"382","article-title":"Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology","volume":"90","author":"Cazzaniga","year":"2005","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.leu.2401277","article-title":"Cross lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease","volume":"13","author":"Szczepa\u0144ski","year":"1999","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V93.12.4079","article-title":"Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage","volume":"93","author":"Szczepa\u0144ski","year":"1999","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/sj.leu.2400887","article-title":"Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations","volume":"11","author":"Langerak","year":"1997","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/sj.leu.2403008","article-title":"Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring","volume":"17","author":"Germano","year":"2003","journal-title":"Leukemia."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/sj.leu.2401801","article-title":"Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia","volume":"14","author":"Verhagen","year":"2000","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","volume":"24","author":"Bruggemann","year":"2010","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1038\/sj.leu.2403081","article-title":"Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL","volume":"17","author":"Szczepanski","year":"2003","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3324\/haematol.2014.112151","article-title":"Clinical features and outcome of SIL\/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group","volume":"100","author":"D'Angi\u00f2","year":"2015","journal-title":"Haematologica"},{"key":"B49","first-page":"275","article-title":"A multiplex reverse transcriptase polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia","volume":"88","author":"Elia","year":"2003","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1365-2141.2003.04393.x","article-title":"Determination of minimal residual disease in leukaemia patients","volume":"121","author":"Campana","year":"2003","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0413-0","article-title":"Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR ofe1a2 BCR-ABL1","author":"Pfeifer","year":"2019","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.leu.2404082","article-title":"Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations","volume":"20","author":"Burmeister","year":"2006","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/088922201750063160","article-title":"Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA","volume":"17","author":"Leutenegger","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia."},{"key":"B56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.tibtech.2013.04.008","article-title":"Overview of clinical flow cytometry data analysis: recent advances and future challenges","volume":"31","author":"Pedreira","year":"2013","journal-title":"Trends Biotechnol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/sj.leu.2403559","article-title":"I-BFM-ALL-FCM-MRD study group. Drug induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection","volume":"19","author":"Gaipa","year":"2005","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"lores-Montero","year":"2017","journal-title":"Leukemia."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1373\/clinchem.2013.214742","article-title":"Digital PCR as a novel technology and its potential implications for molecular diagnostics","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin Chem"},{"key":"B62","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1021\/ac202578x","article-title":"Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification","volume":"84","author":"Pinheiro","year":"2012","journal-title":"Anal Chem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1021\/ac103230c","article-title":"Evaluation of digital PCR for absolute DNA quantification","volume":"83","author":"Sanders","year":"2011","journal-title":"Anal Chem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1093\/nar\/gks203","article-title":"Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation","volume":"40","author":"Whale","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"key":"B67","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1039\/b917851a","article-title":"Microfluidic stochastic confinement enhances analysis of rare cells by isolating cells and creating high density environments for control of diffusible signals","volume":"39","author":"Vincent","year":"2010","journal-title":"Chem Soc Rev"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ijpara.2014.08.004","article-title":"Comparison of next-generation droplet digital PCR (ddPCR) with quantitative PCR (qPCR) for enumeration of Cryptosporidium oocysts in faecal samples","volume":"44","author":"Yang","year":"2014","journal-title":"Int J Parasitol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/blood-2010-10-310789","article-title":"Non invasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA","volume":"117","author":"Tsui","year":"2011","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/ejh.12246","article-title":"Detection of alpha (0)-thalassemia South-East Asian-type deletion by droplet digital PCR","volume":"92","author":"Pornprasert","year":"2014","journal-title":"Eur J Haematol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.exphem.2015.02.006","article-title":"Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation","volume":"43","author":"Stahl","year":"2015","journal-title":"Exp Hematol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00428-015-1802-z","article-title":"BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR","volume":"467","author":"Zagaria","year":"2015","journal-title":"Virchows Archiv"},{"key":"B73","doi-asserted-by":"publisher","first-page":"13269","DOI":"10.18632\/oncotarget.3773","article-title":"Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia","volume":"6","author":"Albano","year":"2015","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jmoldx.2018.03.002","article-title":"Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"20","author":"Coccaro","year":"2018","journal-title":"J Mol Diagn"},{"key":"B75","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"key":"B76","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.14082","article-title":"Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin\/Tcell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia","volume":"174","author":"Della Starza","year":"2016","journal-title":"Br J Haematol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.14616","article-title":"Comparative analysis between RQ-PCR and digital droplet PCR of BCL2\/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma","volume":"177","author":"Cavalli","year":"2017","journal-title":"Br J Haematol"},{"key":"B78","first-page":"S1","article-title":"Minimal residual disease (MRD) detection by digital-droplet-PCR (ddPCR) in lymphoid malignancies","volume":"103","author":"Della Starza","year":"2018","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2018-99-117954","article-title":"Digital-droplet PCR, an accurate method for IG\/TR PCR-MRD stratification in childhood acute lymphoblastic leukemia","volume":"132","author":"Della Starza","year":"2018","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","article-title":"The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL","volume":"126","author":"Kotrova","year":"2015","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/leu.2011.89","article-title":"Very early\/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment","volume":"25","author":"Eckert","year":"2011","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/bmt.2017.16","article-title":"Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL","volume":"52","author":"Kotrova","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood-2018-99-118219","article-title":"Comparative analysis between RQ-PCR, digital-droplet-PCR and Next-Generation-Sequencing (NGS) of immunoglobulin\/T-cell receptor gene rearrangements to monitor minimal residual disease in adult acute lymphoblastic leukemia patients","volume":"132","author":"Della Starza","year":"2018","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","article-title":"Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle","volume":"39","author":"Br\u00fcggemann","year":"2012","journal-title":"Semin Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"G\u00f6kbuget","year":"2019","journal-title":"Hematology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ejh.12587","article-title":"Czech Leukemia Study Group - for Life. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia","volume":"96","author":"Salek","year":"2016","journal-title":"Eur J Haematol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1002\/cncr.30262","article-title":"Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"122","author":"Short","year":"2016","journal-title":"Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"GRAALL group. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V128.22.176.176","article-title":"Final results of Northern Italy Leukemia Group (NILG) trial 10\/07 combining pediatric-type therapy with minimal residual disease study and risk-oriented hematopoietic cell transplantation in adult acute lymphoblastic leukemia (ALL)","volume":"128","author":"Bassan","year":"2016","journal-title":"Blood"},{"key":"B95","first-page":"PS919","article-title":"First results of new GIMEMA trial LAL 1913 for adult patients with Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL)","volume-title":"23th EHA Annual Congress Stockolm, 14-17 June","author":"Bassan","year":"2018"},{"key":"B96","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1365-2141.2009.07941.x","article-title":"Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993","volume":"148","author":"Patel","year":"2010","journal-title":"Br J Haematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/bmt.2009.308","article-title":"Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL","volume":"45","author":"Giebel","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1038\/bcj.2014.48","article-title":"Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia","volume":"4","author":"Bassan","year":"2014","journal-title":"Blood Cancer J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s12032-014-0938-z","article-title":"Clinical significance of minimal residual disease in young adults with standard-risk\/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study","volume":"31","author":"Salah-Eldin","year":"2014","journal-title":"Med Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3324\/haematol.2015.127837","article-title":"Personalized medicine in adult acute lymphoblastic leukemia","volume":"100","author":"Hoelzer","year":"2015","journal-title":"Haematologica"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdw123","article-title":"Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"27","author":"Yoon","year":"2016","journal-title":"Ann Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1586\/14737140.2014.895669","article-title":"Current and future management of Ph\/BCRABL positive ALL","volume":"14","author":"Maino","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","article-title":"A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study","volume":"101","author":"Chiaretti","year":"2016","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2012.164","article-title":"Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"26","author":"Lee","year":"2012","journal-title":"Leukemia"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1038\/bcj.2012.18","article-title":"Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL positive ALL","volume":"2","author":"Mizuta","year":"2012","journal-title":"Blood Cancer J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood.V126.23.81.81","article-title":"Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic based prognostic stratification","volume":"126","author":"Chiaretti","year":"2015","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","article-title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.bbmt.2016.07.021","article-title":"Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome","volume":"22","author":"Lussana","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B114","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/bjh.13834","article-title":"Minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia","volume":"172","author":"Ravandi","year":"2016","journal-title":"Br J Haematol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/bmt.2015.217","article-title":"Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ ALL: a study from the adult ALL WG of the JSHCT","volume":"51","author":"Nishiwaki","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase, I. I, Single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2017.176917","article-title":"Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin\/T-cell receptor and BCR\/ABL1 methodologies","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"key":"B118","first-page":"S1568","article-title":"Persistent BCR-ABL1 clonal hematopoiesis after blast clearance identifies a CML-like subgroup of patients with Philadelphia chromosome-positive (Ph+) ALL: Interim results from GRAAPH-2014 trial","volume-title":"23th EHA Annual Congress Stockolm, 14-17 June","author":"Clappier","year":"2018"},{"key":"B119","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. Intergroup Trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood."},{"key":"B121","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B122","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","article-title":"The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Zhou","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B124","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.bbmt.2014.05.026","article-title":"Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia","volume":"20","author":"Terwey","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B126","doi-asserted-by":"publisher","first-page":"421723","DOI":"10.1155\/2014\/421723","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leuk Res Treatment"},{"key":"B127","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1200\/JCO.2010.30.2877","article-title":"Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition","volume":"29","author":"Szczepanski","year":"2011","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bjh.15056","article-title":"A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children","volume":"180","author":"Sutton","year":"2018","journal-title":"Br J Haematol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"Loffler","year":"2003","journal-title":"Leukemia"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B135","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"G\u00f6kbuget","year":"2017","journal-title":"Haematologica"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00726\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T04:04:00Z","timestamp":1575518640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00726\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":147,"alternative-id":["10.3389\/fonc.2019.00726"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00726","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"article-number":"726"}}